Fatty acid synthase in liver disease

Title: Fatty acid synthase in liver disease

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20090162870, Fatty acid synthase in liver disease.

What is claimed is:

1. A method of detecting elevated fatty acid synthase (FAS) in the liver of a subject, said method comprising detecting or measuring the level of fatty acid synthase (FAS) in a bodily fluid sample from a subject suspected of being, or diagnosed as, cancer-free, wherein an elevated level of FAS indicates elevated FAS in the liver of said subject.

2. The method of claim 1 further comprising identifying the presence or absence of liver disease in said subject, wherein i) a level of FAS that is elevated, relative to the level in a subject without liver disease, identifies the presence of liver disease in said subject, and ii) a level of FAS that is the same, relative to the level in a subject without liver disease, identifies the absence of liver disease in said subject.

3. The method of claim 2 wherein said liver disease is characterized by an elevated level of FAS is steatohepatitis, such as non-alcoholic steatohepatitis or alcoholic hepatitis; or not characterized by an elevated level of FAS, such as liver toxicity; viral infection of the liver, or viral hepatitis; autoimmune hepatitis; cryptogenic cirrhosis; hepatic necrosis following hypoperfusion; and hepatitis resulting from other disease.

4. The method of claim 3 wherein said liver toxicity is due to exposure of the subject to an exogenous drug or chemical agent, such as tetracycline or carbon tetrachloride; said viral infection or viral hepatitis is selected from Hepatitis A, B, C, or D, or is due to infection by cytomegalovirus or herpesvirus; said autoimmune hepatitis is due to systemic lupus erythematosis, scleroderma, or CREST syndrome in said subject; said hepatic necrosis following hypoperfusion is selected from severe hypotension, mechanical injury to the liver, or vascular compromise; or said hepatitis resulting from other disease is selected from ulcerative colitis, Crohn\'s disease, or sclerosing cholangitis.

5. The method of claim 1 wherein said subject is human.

6. The method of claim 1 wherein said bodily fluid is blood or serum.

7. The method of claim 1 wherein said detecting or measuring comprises forming and detecting or measuring a complex between a FAS binding antibody, or antibody fragment, and FAS, if present, in said sample.

8. The method of claim 7, wherein said detecting or measuring is by ELISA or a lateral flow test strip.

9. The method of claim 1 further comprising communicating the level of FAS to said subject.

10. The method of claim 2 wherein said subject is suspected of being afflicted with a liver disease, optionally before the onset of symptoms of cirrhosis.

11. A method of detecting elevated fatty acid synthase (FAS) in the liver of a subject, said method comprising detecting or measuring the level of fatty acid synthase (FAS) expression in a sample comprising liver cells from a subject, wherein an elevated level of FAS expression indicates elevated FAS in the liver of said subject.

12. The method of claim 11 further comprising identifying the presence or absence of liver disease in said subject, wherein i) a level of FAS that is elevated, relative to the level in a subject without liver disease, identifies the presence of liver disease in said subject, and ii) a level of FAS that is the same, relative to the level in a subject without liver disease, identifies the absence of liver disease in said subject.

13. The method of claim 12 wherein said liver disease is selected from steatohepatitis (non-alcoholic steatohepatitis or alcoholic hepatitis); alcoholic hepatitis; liver toxicity; viral infection of the liver, or viral hepatitis; autoimmune hepatitis; cryptogenic cirrhosis; hepatic necrosis following hypoperfusion; and hepatitis resulting from other disease.

14. The method of claim 13 wherein said liver toxicity is due to exposure of the subject to an exogenous drug or chemical agent, such as tetracycline or carbon tetrachloride; said viral infection or viral hepatitis is selected from Hepatitis A, B, C, or D, or is due to infection by cytomegalovirus or herpesvirus; said autoimmune hepatitis is due to systemic lupus erythematosis, scleroderma, or CREST syndrome in said subject; said hepatic necrosis following hypoperfusion is selected from severe hypotension, mechanical injury to the liver, or vascular compromise; or said hepatitis resulting from other disease is selected from ulcerative colitis, Crohn\'s disease, or sclerosing cholangitis.

15. The method of claim 11 wherein said subject is human; or said bodily fluid is blood or serum; or further comprising communicating the level of FAS to said subject.

16. The method of claim 11 wherein said detecting or measuring comprises forming and detecting or measuring a complex between a FAS binding antibody, or antibody fragment, and FAS, if present, in said sample.

17. The method of claim 16, wherein said detecting or measuring is by ELISA or a lateral flow test strip.

18. The method of claim 12 wherein said subject is suspected of being afflicted with a liver disease, optionally before the onset of symptoms of cirrhosis.

19. A method of detecting fat accumulation in the liver of a subject, said method comprising detecting or measuring the level of fatty acid synthase (FAS) expression in a sample comprising liver cells from a subject, wherein an elevated level of FAS indicates accumulation of fat synthesized de novo in the liver of said subject.

20. The method of claim 20 further comprising detection of liver inflammation, wherein the absence of inflammation indicates the presence of steatosis and the presence of inflammation indicates the presence of steatohepatitis; or wherein said level of FAS expression indicates that greater than about 5% of the total liver weight, or more than about 30% of liver cells in a liver lobule, are with fat deposit.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Fatty acid synthase in liver disease patent application.
###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Fatty acid synthase in liver disease or other areas of interest.
###

Previous Patent Application:
Peptide diagnostic agent for lyme disease
Next Patent Application:
Mutants of the factor vii-activating protease and detection methods using specific antibodies
Industry Class:
Chemistry: molecular biology and microbiology

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Fatty acid synthase in liver disease patent info.
IP-related news and info

Results in 1.9599 seconds

Other interesting Feshpatents.com categories:
Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , paws

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO